The European Commission’s approval of Luxturna for inherited retinal disease was the most-read retina-related article on Healio.com/OSN in November. Other top news included clinical trial updates from Clearside and Adverum.
Here are the top five most-read retina articles of the month:
Europe approves first gene therapy for retinal dystrophy
On Nov. 23, the European Commission approved the first gene therapy for the treatment of inherited retinal disease related to a mutation of the RPE65 gene. Luxturna will be authorized in all 28 EU member states as well as Norway, Iceland and
Uncategorized